The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance

1 Abdallah M., Olafisoye O., Cortes C., Urban C., Landman D., Quale J.: Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother. 59, 1802–1805 (2015) AbdallahM. OlafisoyeO. CortesC. UrbanC. LandmanD. QualeJ. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City Antimicrob. Agents Chemother. 59 1802 1805 2015 10.1128/AAC.04809-14432580925534744 Search in Google Scholar

2 Alexander E., Schranz J., et al.: Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. Jama, 322, 1661–1671 (2019) AlexanderE. SchranzJ. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial Jama 322 1661 1671 2019 10.1001/jama.2019.15468686522431560372 Search in Google Scholar

3 Almer L.S., Hoffrage J.B., Keller E.L., Flamm R.K., Shortridge V.D.: In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 48, 2771–2777 (2004) AlmerL.S. HoffrageJ.B. KellerE.L. FlammR.K. ShortridgeV.D. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms Antimicrob. Agents Chemother. 48 2771 2777 2004 10.1128/AAC.48.7.2771-2777.200443420115215148 Search in Google Scholar

4 Ambler R.P.: The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289, 321–331 (1980) AmblerR.P. The structure of β-lactamases Philos. Trans. R. Soc. Lond. B Biol. Sci. 289 321 331 1980 10.1098/rstb.1980.00496109327 Search in Google Scholar

5 Aoki T., Yamano Y., et al.: Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur. J. Med. Chem. 155, 847–868 (2018) AokiT. YamanoY. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship Eur. J. Med. Chem. 155 847 868 2018 10.1016/j.ejmech.2018.06.01429960205 Search in Google Scholar

6 Asempa T.E., Nicolau D.P., Kuti J.L.: In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, DOI: 10.1128/aac.00997-19 (2019) AsempaT.E. NicolauD.P. KutiJ.L. In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa Antimicrob. Agents Chemother. 63 10.1128/aac.00997-19 2019 Open DOISearch in Google Scholar

7 Barnes M.D., Bethel C.R., Alsop J., Becka S.A., Rutter J.D., Papp-Wallace K.M., Bonomo R.A.: Inactivation of the Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam. Antimicrob. Agents Chemother. 62, DOI: 10.1128/aac.02406-17 (2018) BarnesM.D. BethelC.R. AlsopJ. BeckaS.A. RutterJ.D. Papp-WallaceK.M. BonomoR.A. Inactivation of the Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam Antimicrob. Agents Chemother. 62 10.1128/aac.02406-17 2018 Open DOISearch in Google Scholar

8 Bassetti M., Nagata T.D., et al.: Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect. Dis. 21, 226–240 (2021) BassettiM. NagataT.D. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Lancet Infect. Dis. 21 226 240 2021 10.1016/S1473-3099(20)30796-933058795 Search in Google Scholar

9 Bassetti M., Giacobbe D.R., Patel N., Tillotson G., Massey J.: Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis. Adv. Ther. 36, 1771–1777 (2019) BassettiM. GiacobbeD.R. PatelN. TillotsonG. MasseyJ. Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis Adv. Ther. 36 1771 1777 2019 10.1007/s12325-019-00981-y682445931098989 Search in Google Scholar

10 Bhowmick T.: Clinical outcomes of patient subgroups in the TANGO II study. Infect. Dis. Ther. 10, 35–46 (2021) BhowmickT. Clinical outcomes of patient subgroups in the TANGO II study Infect. Dis. Ther. 10 35 46 2021 10.1007/s40121-021-00405-x787211333565042 Search in Google Scholar

11 Biagi M., Wu T., Lee M., Patel S., Butler D., Wenzler E.: Searching for the optimal treatment for metallo- and serine-β-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob. Agents Chemother. 63, DOI: 10.1128/aac.01426-19 (2019) BiagiM. WuT. LeeM. PatelS. ButlerD. WenzlerE. Searching for the optimal treatment for metallo- and serine-β-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam Antimicrob. Agents Chemother. 63 10.1128/aac.01426-19 2019 Open DOISearch in Google Scholar

12 Blizzard T.A., Hammond M.L., et al.: Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin^®. Bioorg. Med. Chem. Lett. 24, 780–785 (2014) BlizzardT.A. HammondM.L. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin^® Bioorg. Med. Chem. Lett. 24 780 785 2014 10.1016/j.bmcl.2013.12.10124433862 Search in Google Scholar

13 Brodersen D.E., Clemons W.M., Jr., Carter A.P., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V.: The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell, 103, 1143–1154 (2000) BrodersenD.E. ClemonsW.M.Jr. CarterA.P. Morgan-WarrenR.J. WimberlyB.T. RamakrishnanV. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit Cell 103 1143 1154 2000 10.1016/S0092-8674(00)00216-6 Search in Google Scholar

14 Castanheira M., Huband M.D., Mendes R.E., Flamm R.K.: Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 61, e00567–17 (2017) CastanheiraM. HubandM.D. MendesR.E. FlammR.K. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae Antimicrob. Agents Chemother. 61 e00567 17 2017 10.1128/AAC.00567-17557130428652234 Search in Google Scholar

15 Castanheira M., Rhomberg P.R., Flamm R.K., Jones R.N.: Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 60, 5454–5458 (2016) CastanheiraM. RhombergP.R. FlammR.K. JonesR.N. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae Antimicrob. Agents Chemother. 60 5454 5458 2016 10.1128/AAC.00711-16499782227381386 Search in Google Scholar

16 Chen C., Liu Y.H., et al.: Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species. Genome Med. 12, DOI:10.1186/s13073-020-00807-5 (2020) ChenC. LiuY.H. Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species Genome Med. 12 10.1186/s13073-020-00807-5 2020 772244933287863 Open DOISearch in Google Scholar

17 Chen C., Sun J., et al.: Emergence of mobile tigecycline resistance mechanism in Escherichia coli strains from migratory birds in China. Emerg. Microbes Infect. 8, 1219–1222 (2019) ChenC. SunJ. Emergence of mobile tigecycline resistance mechanism in Escherichia coli strains from migratory birds in China Emerg. Microbes Infect. 8 1219 1222 2019 10.1080/22221751.2019.1653795671315531429665 Search in Google Scholar

18 Ding Y., Saw W.Y., Tan L.W.L., Moong D.K.N., Nagarajan N., Teo Y.Y., Seedorf H.: Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans. J. Antimicrob. Chemother. 75, 3480–3484 (2020) DingY. SawW.Y. TanL.W.L. MoongD.K.N. NagarajanN. TeoY.Y. SeedorfH. Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans J. Antimicrob. Chemother. 75 3480 3484 2020 10.1093/jac/dkaa37232853333 Search in Google Scholar

19 Durka K., Laudy A.E., Charzewski Ł., Urban M., Stępień K., Tyski S., Krzyśko K.A., Luliński S.: Antimicrobial and KPC/AmpC inhibitory activity of functionalized benzosiloxaboroles. Eur. J. Med. Chem. 171, 11–24 (2019) DurkaK. LaudyA.E. CharzewskiŁ. UrbanM. StępieńK. TyskiS. KrzyśkoK.A. LulińskiS. Antimicrobial and KPC/AmpC inhibitory activity of functionalized benzosiloxaboroles Eur. J. Med. Chem. 171 11 24 2019 10.1016/j.ejmech.2019.03.02830904754 Search in Google Scholar

20 European Medicines Agency: Medicines. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human (16.07.2021) European Medicines Agency Medicines https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human (16.07.2021) Search in Google Scholar

21 Eyal Z., Matzov D., Krupkin M., Paukner S., Riedl R., Rozenberg H., Zimmerman E., Bashan A., Yonath A.: A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci. Rep. 6, DOI:10.1038/srep39004 (2016) EyalZ. MatzovD. KrupkinM. PauknerS. RiedlR. RozenbergH. ZimmermanE. BashanA. YonathA. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism Sci. Rep. 6 10.1038/srep39004 2016 515418827958389 Open DOISearch in Google Scholar

22 File T.M., Gasink L.B., et al.: Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin. Infect. Dis. 69, 1856–1867 (2019) FileT.M. GasinkL.B. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial Clin. Infect. Dis. 69 1856 1867 2019 10.1093/cid/ciz090685369430722059 Search in Google Scholar

23 Fyfe C., LeBlanc G., Close B., Nordmann P., Dumas J., Grossman T.H.: Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1. Antimicrob. Agents Chemother. 60, 6989–6990 (2016) FyfeC. LeBlancG. CloseB. NordmannP. DumasJ. GrossmanT.H. Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1 Antimicrob. Agents Chemother. 60 6989 6990 2016 10.1128/AAC.01646-16507512627550359 Search in Google Scholar

24 Gaibani P., Lombardo D., Bussini L., Bovo F., Munari B., Giannella M., Bartoletti M., Viale P., Lazzarotto T., Ambretti S.: Epidemiology of meropenem/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018. Antibiotics, 10, DOI:10.3390/antibiotics10050536 (2021) GaibaniP. LombardoD. BussiniL. BovoF. MunariB. GiannellaM. BartolettiM. VialeP. LazzarottoT. AmbrettiS. Epidemiology of meropenem/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018 Antibiotics 10 10.3390/antibiotics10050536 2021 814811934066420 Open DOISearch in Google Scholar

25 Gainey A.B., Burch A.K., Brownstein M.J., Brown D.E., Fackler J., Horne B., Biswas B., Bivens B.N., Malagon F., Daniels R.: Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr. Pulmonol. 55, 2990–2994 (2020) GaineyA.B. BurchA.K. BrownsteinM.J. BrownD.E. FacklerJ. HorneB. BiswasB. BivensB.N. MalagonF. DanielsR. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient Pediatr. Pulmonol. 55 2990 2994 2020 10.1002/ppul.2494532662948 Search in Google Scholar

26 Ghai I., Ghai S.: Exploring bacterial outer membrane barrier to combat bad bugs. Infect. Drug Resist. 10, 261–273 (2017) GhaiI. GhaiS. Exploring bacterial outer membrane barrier to combat bad bugs Infect. Drug Resist. 10 261 273 2017 10.2147/IDR.S144299558713128919790 Search in Google Scholar

27 Giacobbe D.R., Ciacco E., Girmenia C., Pea F., Rossolini G.M., Sotgiu G., Tascini C., Tumbarello M., Viale P., Bassetti M.: Evaluating cefiderocol in the treatment of multidrug-resistant Gram-negative bacilli: a review of the emerging data. Infect. Drug Resist. 13, 4697–4711 (2020) GiacobbeD.R. CiaccoE. GirmeniaC. PeaF. RossoliniG.M. SotgiuG. TasciniC. TumbarelloM. VialeP. BassettiM. Evaluating cefiderocol in the treatment of multidrug-resistant Gram-negative bacilli: a review of the emerging data Infect. Drug Resist. 13 4697 4711 2020 10.2147/IDR.S205309777837833402840 Search in Google Scholar

28 Giulieri S.G., Tong S.Y.C., Williamson D.A.: Using genomics to understand methicillin- and vancomycin-resistant Staphylococcus aureus infections. Microb. Genom. 6, DOI: 10.1099/mgen.0.000324 (2020) GiulieriS.G. TongS.Y.C. WilliamsonD.A. Using genomics to understand methicillin- and vancomycin-resistant Staphylococcus aureus infections Microb. Genom. 6 10.1099/mgen.0.000324 2020 706703331913111 Open DOISearch in Google Scholar

29 Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H.T.: In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother. 47, 3008–3011 (2003) GoldsteinE.J. CitronD.M. MerriamC.V. WarrenY.A. TyrrellK.L. FernandezH.T. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis Antimicrob. Agents Chemother. 47 3008 3011 2003 10.1128/AAC.47.9.3008-3011.200318260212937015 Search in Google Scholar

30 Gomez-Simmonds A., Stump S., Giddins M.J., Annavajhala M.K., Uhlemann A.C.: Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae. Antimicrob. Agents Chemother. 62, DOI:10.1128/aac.00573-18 (2018) Gomez-SimmondsA. StumpS. GiddinsM.J. AnnavajhalaM.K. UhlemannA.C. Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae Antimicrob. Agents Chemother. 62 10.1128/aac.00573-18 2018 610579229891602 Open DOISearch in Google Scholar

31 Grossman T.H.: Tetracycline antibiotics and resistance. Cold Spring Harb. Perspect. Med. 6, DOI:10.1101/cshperspect.a025387 (2016) GrossmanT.H. Tetracycline antibiotics and resistance Cold Spring Harb. Perspect. Med. 6 10.1101/cshperspect.a025387 2016 481774026989065 Open DOISearch in Google Scholar

32 Grossman T.H., O’Brien W., Kerstein K.O., Sutcliffe J.A.: Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob. Agents Chemother. 59, 2446–2449 (2015) GrossmanT.H. O’BrienW. KersteinK.O. SutcliffeJ.A. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli Antimicrob. Agents Chemother. 59 2446 2449 2015 10.1128/AAC.04967-14435679225624334 Search in Google Scholar

33 Grossman T.H., Starosta A.L., Fyfe C., O’Brien W., Rothstein D.M., Mikolajka A., Wilson D.N., Sutcliffe J.A.: Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother. 56, 2559–2564 (2012) GrossmanT.H. StarostaA.L. FyfeC. O’BrienW. RothsteinD.M. MikolajkaA. WilsonD.N. SutcliffeJ.A. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic Antimicrob. Agents Chemother. 56 2559 2564 2012 10.1128/AAC.06187-11334660522354310 Search in Google Scholar

34 Gunderson S.M., Hayes R.A., Quinn J.P., Danziger L.H.: In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 48, 203–208 (2004) GundersonS.M. HayesR.A. QuinnJ.P. DanzigerL.H. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Antimicrob. Agents Chemother. 48 203 208 2004 10.1128/AAC.48.1.203-208.200431016614693540 Search in Google Scholar

35 Hackel M.A., Tsuji M., Yamano Y., Echols R., Karlowsky J.A., Sahm D.F.: In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob. Agents Chemother. 62, DOI:10.1128/aac.01968-17 (2018) HackelM.A. TsujiM. YamanoY. EcholsR. KarlowskyJ.A. SahmD.F. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016 Antimicrob. Agents Chemother. 62 10.1128/aac.01968-17 2018 Open DOISearch in Google Scholar

36 Haidar G., Clancy C.J., Chen L., Samanta P., Shields R.K., Kreiswirth B.N., Nguyen M.H.: Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.00642-17 (2017) HaidarG. ClancyC.J. ChenL. SamantaP. ShieldsR.K. KreiswirthB.N. NguyenM.H. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae Antimicrob. Agents Chemother. 61 10.1128/aac.00642-17 2017 557134328630202 Open DOISearch in Google Scholar

37 Hammoudi Halat D., Ayoub Moubareck C.: The current burden of carbapenemases: review of significant properties and dissemination among Gram-negative bacteria. Antibiotics, 9, DOI:10.3390/antibiotics9040186 (2020) Hammoudi HalatD. Ayoub MoubareckC. The current burden of carbapenemases: review of significant properties and dissemination among Gram-negative bacteria Antibiotics 9 10.3390/antibiotics9040186 2020 723576932316342 Open DOISearch in Google Scholar

38 He D., Wang L., Zhao S., Liu L., Liu J., Hu G., Pan Y.: A novel tigecycline resistance gene, tet(X6), on an SXT/R391 integrative and conjugative element in a Proteus genomospecies 6 isolate of retail meat origin. J. Antimicrob. Chemother. 75, 1159–1164 (2020) HeD. WangL. ZhaoS. LiuL. LiuJ. HuG. PanY. A novel tigecycline resistance gene, tet(X6), on an SXT/R391 integrative and conjugative element in a Proteus genomospecies 6 isolate of retail meat origin J. Antimicrob. Chemother. 75 1159 1164 2020 10.1093/jac/dkaa01232016288 Search in Google Scholar

39 Hecker S.J., Dudley M.N., et al.: Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J. Med. Chem. 58, 3682–3692 (2015) HeckerS.J. DudleyM.N. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases J. Med. Chem. 58 3682 3692 2015 10.1021/acs.jmedchem.5b0012725782055 Search in Google Scholar

40 Hirsch E.B., Ledesma K.R., Chang K.T., Schwartz M.S., Motyl M.R., Tam V.H.: In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 56, 3753–3757 (2012) HirschE.B. LedesmaK.R. ChangK.T. SchwartzM.S. MotylM.R. TamV.H. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria Antimicrob. Agents Chemother. 56 3753 3757 2012 10.1128/AAC.05927-11339346022526311 Search in Google Scholar

41 Hook E.W., 3rd, Golden M.R., Taylor S.N., Henry E., Tseng C., Workowski K.A., Swerdlow J., Nenninger A., Cammarata S.: Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study. Sex. Transm. Dis. 46, 279–286 (2019) HookE.W.3rd GoldenM.R. TaylorS.N. HenryE. TsengC. WorkowskiK.A. SwerdlowJ. NenningerA. CammarataS. Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study Sex. Transm. Dis. 46 279 286 2019 10.1097/OLQ.000000000000097130985632 Search in Google Scholar

42 Hooper D.C., Jacoby G.A.: Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 6, DOI:10.1101/cshperspect.a025320 (2016) HooperD.C. JacobyG.A. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance Cold Spring Harb. Perspect. Med. 6 10.1101/cshperspect.a025320 2016 500806027449972 Open DOISearch in Google Scholar

43 Hoover R., Hunt T., Benedict M., Paulson S.K., Lawrence L., Cammarata S., Sun E.: Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin. Ther. 38, 53–65 (2016) HooverR. HuntT. BenedictM. PaulsonS.K. LawrenceL. CammarataS. SunE. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers Clin. Ther. 38 53 65 2016 10.1016/j.clinthera.2015.11.01926718605 Search in Google Scholar

44 Hoover R., Hunt T., Benedict M., Paulson S.K., Lawrence L., Cammarata S., Sun E.: Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin. Ther. 38, 39–52 (2016) HooverR. HuntT. BenedictM. PaulsonS.K. LawrenceL. CammarataS. SunE. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age Clin. Ther. 38 39 52 2016 10.1016/j.clinthera.2015.10.01626581327 Search in Google Scholar

45 Horcajada J.P., Salata R.A., Álvarez-Sala R., Nitu F.M., Lawrence L., Quintas M., Cheng C.Y., Cammarata S.: A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect. Dis. 7, DOI:10.1093/ofid/ofz514 (2020) HorcajadaJ.P. SalataR.A. Álvarez-SalaR. NituF.M. LawrenceL. QuintasM. ChengC.Y. CammarataS. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP) Open Forum Infect. Dis. 7 10.1093/ofid/ofz514 2020 697525131988972 Open DOISearch in Google Scholar

46 Ito-Horiyama T., Ishii Y., Ito A., Sato T., Nakamura R., Fukuhara N., Tsuji M., Yamano Y., Yamaguchi K., Tateda K.: Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob. Agents Chemother. 60, 4384–4386 (2016) Ito-HoriyamaT. IshiiY. ItoA. SatoT. NakamuraR. FukuharaN. TsujiM. YamanoY. YamaguchiK. TatedaK. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases Antimicrob. Agents Chemother. 60 4384 4386 2016 10.1128/AAC.03098-15491468827139465 Search in Google Scholar

47 Ito A., Nishikawa T., Ota M., Ito-Horiyama T., Ishibashi N., Sato T., Tsuji M., Yamano Y.: Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J. Antimicrob. Chemother. 73, 3049–3052 (2018) ItoA. NishikawaT. OtaM. Ito-HoriyamaT. IshibashiN. SatoT. TsujiM. YamanoY. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae J. Antimicrob. Chemother. 73 3049 3052 2018 10.1093/jac/dky317619874330188999 Search in Google Scholar

48 Ito A., Yamano Y., et al.: In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob. Agents Chemother. 62, DOI:10.1128/aac.01454-17 (2018) ItoA. YamanoY. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria Antimicrob. Agents Chemother. 62 10.1128/aac.01454-17 2018 Open DOISearch in Google Scholar

49 Jacobsson S., Paukner S., Golparian D., Jensen J.S., Unemo M.: In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.01497-17 (2017) JacobssonS. PauknerS. GolparianD. JensenJ.S. UnemoM. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae Antimicrob. Agents Chemother. 61 10.1128/aac.01497-17 2017 Open DOISearch in Google Scholar

50 Johnson J.R., Porter S.B., Johnston B.D., Thuras P.: Activity of eravacycline against Escherichia coli clinical isolates collected from U.S. veterans in 2011 in relation to coresistance phenotype and sequence Type 131 genotype. Antimicrob. Agents Chemother. 60, 1888–1891 (2015) JohnsonJ.R. PorterS.B. JohnstonB.D. ThurasP. Activity of eravacycline against Escherichia coli clinical isolates collected from U.S. veterans in 2011 in relation to coresistance phenotype and sequence Type 131 genotype Antimicrob. Agents Chemother. 60 1888 1891 2015 10.1128/AAC.02403-15477594126666925 Search in Google Scholar

51 Johnston B.D., Thuras P., Porter S.B., Anacker M., VonBank B., Vagnone P.S., Witwer M., Castanheira M., Johnson J.R.: Activity of imipenem-relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.02408-19 (2020) JohnstonB.D. ThurasP. PorterS.B. AnackerM. VonBankB. VagnoneP.S. WitwerM. CastanheiraM. JohnsonJ.R. Activity of imipenem-relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region Antimicrob. Agents Chemother. 64 10.1128/aac.02408-19 2020 Open DOISearch in Google Scholar

52 Johnston B.D., Thuras P., Porter S.B., Castanheira M., Johnson J.R.: Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. J. Glob. Antimicrob. Resist. 24, 190–197 (2021) JohnstonB.D. ThurasP. PorterS.B. CastanheiraM. JohnsonJ.R. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region J. Glob. Antimicrob. Resist. 24 190 197 2021 10.1016/j.jgar.2020.12.01733460842 Search in Google Scholar

53 Karlowsky J.A., Lob S.H., Kazmierczak K.M., Hawser S.P., Magnet S., Young K., Motyl M.R., Sahm D.F.: In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J. Antimicrob. Chemother. 73, 1872–1879 (2018) KarlowskyJ.A. LobS.H. KazmierczakK.M. HawserS.P. MagnetS. YoungK. MotylM.R. SahmD.F. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme J. Antimicrob. Chemother. 73 1872 1879 2018 10.1093/jac/dky10729659861 Search in Google Scholar

54 Karlowsky J.A., Lob S.H., Kazmierczak K.M., Young K., Motyl M.R., Sahm D.F.: In vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017. Int. J. Antimicrob. Agents, 55, DOI:10.1016/j.ijantimicag.2019.10.022 (2020) KarlowskyJ.A. LobS.H. KazmierczakK.M. YoungK. MotylM.R. SahmD.F. In vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017 Int. J. Antimicrob. Agents 55 10.1016/j.ijantimicag.2019.10.022 2020 31704217 Open DOISearch in Google Scholar

55 Kaye K.S., Giamarellos-Bourboulis E.J., et al.: Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. Jama, 319, 788–799 (2018) KayeK.S. Giamarellos-BourboulisE.J. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial Jama 319 788 799 2018 10.1001/jama.2018.0438583865629486041 Search in Google Scholar

56 Kingsley J., Mehra P., Lawrence L.E., Henry E., Duffy E., Cammarata S.K., Pullman J.: A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J. Antimicrob. Chemother. 71, 821–829 (2016) KingsleyJ. MehraP. LawrenceL.E. HenryE. DuffyE. CammarataS.K. PullmanJ. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin J. Antimicrob. Chemother. 71 821 829 2016 10.1093/jac/dkv411474370326679243 Search in Google Scholar

57 Kocsis B., Domokos J., Szabo D.: Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann. Clin. Microbiol. Antimicrob. 15, DOI:10.1186/s12941-016-0150-4 (2016) KocsisB. DomokosJ. SzaboD. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin Ann. Clin. Microbiol. Antimicrob. 15 10.1186/s12941-016-0150-4 2016 487806727215369 Open DOISearch in Google Scholar

58 Kohira N., Hackel M.A., Ishioka Y., Kuroiwa M., Sahm D.F., Sato T., Maki H., Yamano Y.: Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J. Glob. Antimicrob. Resist. 22, 738–741 (2020) KohiraN. HackelM.A. IshiokaY. KuroiwaM. SahmD.F. SatoT. MakiH. YamanoY. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014) J. Glob. Antimicrob. Resist. 22 738 741 2020 10.1016/j.jgar.2020.07.00932702396 Search in Google Scholar

59 Lapuebla A., Abdallah M., Olafisoye O., Cortes C., Urban C., Quale J., Landman D.: Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob. Agents Chemother. 59, 4856–4860 (2015) LapueblaA. AbdallahM. OlafisoyeO. CortesC. UrbanC. QualeJ. LandmanD. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City Antimicrob. Agents Chemother. 59 4856 4860 2015 10.1128/AAC.00843-15450529326033723 Search in Google Scholar

60 Laudy A.E.: MDR efflux pumps – the mechanism of Gram-negative rods resistance to antibiotics. Post. Mikrobiol. 47, 415–422 (2008) LaudyA.E. MDR efflux pumps – the mechanism of Gram-negative rods resistance to antibiotics Post. Mikrobiol. 47 415 422 2008 Search in Google Scholar

61 Li P., Wei Y., Li G., Cheng H., Xu Z., Yu Z., Deng Q., Shi Y.: Comparison of antimicrobial efficacy of eravacycline and tigecycline against clinical isolates of Streptococcus agalactiae in China: In vitro activity, heteroresistance, and cross-resistance. Microb. Pathog. 149, DOI:10.1016/j.micpath.2020.104502 (2020) LiP. WeiY. LiG. ChengH. XuZ. YuZ. DengQ. ShiY. Comparison of antimicrobial efficacy of eravacycline and tigecycline against clinical isolates of Streptococcus agalactiae in China: In vitro activity, heteroresistance, and cross-resistance Microb. Pathog. 149 10.1016/j.micpath.2020.104502 2020 32947016 Open DOISearch in Google Scholar

62 Livermore D.M., Mushtaq S., Warner M., Woodford N.: In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob. Agents Chemother. 60, 3840–3844 (2016) LivermoreD.M. MushtaqS. WarnerM. WoodfordN. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii Antimicrob. Agents Chemother. 60 3840 3844 2016 10.1128/AAC.00436-16487938227044556 Search in Google Scholar

63 Livermore D.M., Warner M., Mushtaq S.: Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 68, 2286–2290 (2013) LivermoreD.M. WarnerM. MushtaqS. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa J. Antimicrob. Chemother. 68 2286 2290 2013 10.1093/jac/dkt17823696619 Search in Google Scholar

64 Lob S.H., Hackel M.A., Kazmierczak K.M., Young K., Motyl M.R., Karlowsky J.A., Sahm D.F.: In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.02209-16 (2017) LobS.H. HackelM.A. KazmierczakK.M. YoungK. MotylM.R. KarlowskyJ.A. SahmD.F. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program) Antimicrob. Agents Chemother. 61 10.1128/aac.02209-16 2017 Open DOISearch in Google Scholar

65 Lob S.H., Karlowsky J.A., Young K., Motyl M.R., Hawser S., Kothari N.D., Sahm D.F.: In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017. J. Med. Microbiol. 69, 207–217 (2020) LobS.H. KarlowskyJ.A. YoungK. MotylM.R. HawserS. KothariN.D. SahmD.F. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017 J. Med. Microbiol. 69 207 217 2020 10.1099/jmm.0.00114231976856 Search in Google Scholar

66 Lomovskaya O., Sun D., Rubio-Aparicio D., Nelson K., Tsivkovski R., Griffith D.C., Dudley M.N.: Vaborbactam: spectrum of β-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.01443-17 (2017) LomovskayaO. SunD. Rubio-AparicioD. NelsonK. TsivkovskiR. GriffithD.C. DudleyM.N. Vaborbactam: spectrum of β-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae Antimicrob. Agents Chemother. 61 10.1128/aac.01443-17 2017 Open DOISearch in Google Scholar

67 Lucasti C., Paschke A., et al.: Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob. Agents Chemother. 60, 6234–6243 (2016) LucastiC. PaschkeA. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection Antimicrob. Agents Chemother. 60 6234 6243 2016 10.1128/AAC.00633-16503831327503659 Search in Google Scholar

68 Lv L., Liu J.H., et al.: Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae. mBio, 11, DOI:10.1128/mBio.02930-19 (2020) LvL. LiuJ.H. Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae mBio 11 10.1128/mBio.02930-19 2020 706476932127452 Open DOISearch in Google Scholar

69 Malik S., Kaminski M., Landman D., Quale J.: Cefiderocol resistance in Acinetobacter baumannii: roles of β-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.01221-20 (2020) MalikS. KaminskiM. LandmanD. QualeJ. Cefiderocol resistance in Acinetobacter baumannii: roles of β-lactamases, siderophore receptors, and penicillin binding protein 3 Antimicrob. Agents Chemother. 64 10.1128/aac.01221-20 2020 757712632868330 Open DOISearch in Google Scholar

70 Maraki S., Mavromanolaki V.E., Moraitis P., Stafylaki D., Kasimati A., Magkafouraki E., Scoulica E.: Ceftazidime-avibac tam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. DOI:10.1007/s10096-021-04197-3 (2021) MarakiS. MavromanolakiV.E. MoraitisP. StafylakiD. KasimatiA. MagkafourakiE. ScoulicaE. Ceftazidime-avibac tam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae Eur. J. Clin. Microbiol. Infect. Dis. 10.1007/s10096-021-04197-3 2021 33595756 Open DOISearch in Google Scholar

71 McCurdy S., Keedy K., Lawrence L., Nenninger A., Sheets A., Quintas M., Cammarata S.: Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.01949-19 (2020) McCurdyS. KeedyK. LawrenceL. NenningerA. SheetsA. QuintasM. CammarataS. Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial Antimicrob. Agents Chemother. 64 10.1128/aac.01949-19 2020 703830731844013 Open DOISearch in Google Scholar

72 McCurdy S., Lawrence L., Quintas M., Woosley L., Flamm R., Tseng C., Cammarata S.: In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.00772-17 (2017) McCurdyS. LawrenceL. QuintasM. WoosleyL. FlammR. TsengC. CammarataS. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections Antimicrob. Agents Chemother. 61 10.1128/aac.00772-17 2017 Open DOISearch in Google Scholar

73 McCurdy S., Nenninger A., Sheets A., Keedy K., Lawrence L., Quintas M., Cammarata S.: Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial. Int. J. Infect. Dis. 97, 374–379 (2020) McCurdyS. NenningerA. SheetsA. KeedyK. LawrenceL. QuintasM. CammarataS. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial Int. J. Infect. Dis. 97 374 379 2020 10.1016/j.ijid.2020.06.01832534142 Search in Google Scholar

74 Mendes R.E., Farrell D.J., Flamm R.K., Talbot G.H., Ivezic-Schoenfeld Z., Paukner S., Sader H.S.: In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob. Agents Chemother. 60, 4407–4411 (2016) MendesR.E. FarrellD.J. FlammR.K. TalbotG.H. Ivezic-SchoenfeldZ. PauknerS. SaderH.S. In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States Antimicrob. Agents Chemother. 60 4407 4411 2016 10.1128/AAC.00627-16491467527161634 Search in Google Scholar

75 Mendes R.E., Paukner S., Doyle T.B., Gelone S.P., Flamm R.K., Sader H.S.: Low prevalence of Gram-positive isolates showing elevated lefamulin MIC. Results during the SENTRY Surveillance Program for 2015–2016 and characterization of resistance mechanisms. Antimicrob. Agents Chemother. 63, DOI:10.1128/aac.02158-18 (2019) MendesR.E. PauknerS. DoyleT.B. GeloneS.P. FlammR.K. SaderH.S. Low prevalence of Gram-positive isolates showing elevated lefamulin MIC. Results during the SENTRY Surveillance Program for 2015–2016 and characterization of resistance mechanisms Antimicrob. Agents Chemother. 63 10.1128/aac.02158-18 2019 Open DOISearch in Google Scholar

76 Morrissey I., Hawser S., Lob S.H., Karlowsky J.A., Bassetti M., Corey G.R., Olesky M., Newman J., Fyfe C.: In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI: 10.1128/aac.01715-19 (2020) MorrisseyI. HawserS. LobS.H. KarlowskyJ.A. BassettiM. CoreyG.R. OleskyM. NewmanJ. FyfeC. In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017 Antimicrob. Agents Chemother. 64 10.1128/aac.01715-19 2020 Open DOISearch in Google Scholar

77 Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C.: In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI: 10.1128/aac.01699-19 (2020) MorrisseyI. OleskyM. HawserS. LobS.H. KarlowskyJ.A. CoreyG.R. BassettiM. FyfeC. In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017 Antimicrob. Agents Chemother. 64 10.1128/aac.01699-19 2020 Open DOISearch in Google Scholar

78 Motsch J., Paschke A., et al.: RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin. Infect. Dis. 70, 1799–1808 (2020) MotschJ. PaschkeA. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections Clin. Infect. Dis. 70 1799 1808 2020 10.1093/cid/ciz530715677431400759 Search in Google Scholar

79 Namysłowska A., Laudy A.E., Tyski S.: Acinetobacter baumannii mechanisms of resistance to antibacterial agents. Post. Mikrobiol. 54, 392–406 (2015) NamysłowskaA. LaudyA.E. TyskiS. Acinetobacter baumannii mechanisms of resistance to antibacterial agents Post. Mikrobiol. 54 392 406 2015 Search in Google Scholar

80 Negash K.H., Norris J.K.S., Hodgkinson J.T.: Siderophore-antibiotic conjugate design: new drugs for bad bugs? Molecules, 24, DOI:10.3390/molecules24183314 (2019) NegashK.H. NorrisJ.K.S. HodgkinsonJ.T. Siderophore-antibiotic conjugate design: new drugs for bad bugs? Molecules 24 10.3390/molecules24183314 2019 676707831514464 Open DOISearch in Google Scholar

81 Nilius A.M., Shen L.L., Hensey-Rudloff D., Almer L.S., Beyer J.M., Balli D.J., Cai Y., Flamm R.K.: In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. 47, 3260–3269 (2003) NiliusA.M. ShenL.L. Hensey-RudloffD. AlmerL.S. BeyerJ.M. BalliD.J. CaiY. FlammR.K. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone Antimicrob. Agents Chemother. 47 3260 3269 2003 10.1128/AAC.47.10.3260-3269.200320115314506039 Search in Google Scholar

82 O’Riordan W., McManus A., Teras J., Poromanski I., Cruz-Saldariagga M., Quintas M., Lawrence L., Liang S., Cammarata S.: A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure snfections: a phase 3, multinational, souble-blind, randomized study. Clin. Infect. Dis. 67, 657–666 (2018) O’RiordanW. McManusA. TerasJ. PoromanskiI. Cruz-SaldariaggaM. QuintasM. LawrenceL. LiangS. CammarataS. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure snfections: a phase 3, multinational, souble-blind, randomized study Clin. Infect. Dis. 67 657 666 2018 10.1093/cid/ciy165609399529518178 Search in Google Scholar

83 O’Riordan W., Mehra P., Manos P., Kingsley J., Lawrence L., Cammarata S.: A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int. J. Infect. Dis. 30, 67–73 (2015) O’RiordanW. MehraP. ManosP. KingsleyJ. LawrenceL. CammarataS. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections Int. J. Infect. Dis. 30 67 73 2015 10.1016/j.ijid.2014.10.00925448332 Search in Google Scholar

84 Ozger H.S., Cuhadar T., Yildiz S.S., Demirbas Gulmez Z., Dizbay M., Guzel Tunccan O., Kalkanci A., Simsek H., Unaldi O.: In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J. Antibiot. 72, 600–604 (2019) OzgerH.S. CuhadarT. YildizS.S. Demirbas GulmezZ. DizbayM. Guzel TunccanO. KalkanciA. SimsekH. UnaldiO. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates J. Antibiot. 72 600 604 2019 10.1038/s41429-019-0188-631028352 Search in Google Scholar

85 Paukner S., Gelone S.P., Arends S.J.R., Flamm R.K., Sader H.S.: Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016). Antimicrob. Agents Chemother. 63, DOI:10.1128/aac.02161-18 (2019) PauknerS. GeloneS.P. ArendsS.J.R. FlammR.K. SaderH.S. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016) Antimicrob. Agents Chemother. 63 10.1128/aac.02161-18 2019 Open DOISearch in Google Scholar

86 Paukner S., Riedl R.: Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb. Perspect. Med. 7, DOI:10.1101/cshperspect.a027110 (2017) PauknerS. RiedlR. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance Cold Spring Harb. Perspect. Med. 7 10.1101/cshperspect.a027110 2017 520432727742734 Open DOISearch in Google Scholar

87 Paukner S., Sader H.S., Ivezic-Schoenfeld Z., Jones R.N.: Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob. Agents Chemother. 57, 4489–4495 (2013) PauknerS. SaderH.S. Ivezic-SchoenfeldZ. JonesR.N. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010 Antimicrob. Agents Chemother. 57 4489 4495 2013 10.1128/AAC.00358-13375434023836172 Search in Google Scholar

88 Pfaller M.A., Huband M.D., Mendes R.E., Flamm R.K., Castanheira M.: In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Int. J. Antimicrob. Agents, 52, 144–150 (2018) PfallerM.A. HubandM.D. MendesR.E. FlammR.K. CastanheiraM. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme Int. J. Antimicrob. Agents 52 144 150 2018 10.1016/j.ijantimicag.2018.02.02129510189 Search in Google Scholar

89 Portsmouth S., van Veenhuyzen D., Echols R., Machida M., Ferreira J.C.A., Ariyasu M., Tenke P., Nagata T.D.: Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 18, 1319–1328 (2018) PortsmouthS. van VeenhuyzenD. EcholsR. MachidaM. FerreiraJ.C.A. AriyasuM. TenkeP. NagataT.D. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial Lancet Infect. Dis. 18 1319 1328 2018 10.1016/S1473-3099(18)30554-130509675 Search in Google Scholar

90 Prince W.T., Ivezic-Schoenfeld Z., Lell C., Tack K.J., Novak R., Obermayr F., Talbot G.H.: Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 57, 2087–2094 (2013) PrinceW.T. Ivezic-SchoenfeldZ. LellC. TackK.J. NovakR. ObermayrF. TalbotG.H. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections Antimicrob. Agents Chemother. 57 2087 2094 2013 10.1128/AAC.02106-12363289223422913 Search in Google Scholar

91 Pullman J., Gardovskis J., Farley B., Sun E., Quintas M., Lawrence L., Ling R., Cammarata S.: Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J. Antimicrob. Chemother. 72, 3471–3480 (2017) PullmanJ. GardovskisJ. FarleyB. SunE. QuintasM. LawrenceL. LingR. CammarataS. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study J. Antimicrob. Chemother. 72 3471 3480 2017 10.1093/jac/dkx329589068629029278 Search in Google Scholar

92 Remy J.M., Tow-Keogh C.A., McConnell T.S., Dalton J.M., Devito J.A.: Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J. Antimicrob. Chemother. 67, 2814–2820 (2012) RemyJ.M. Tow-KeoghC.A. McConnellT.S. DaltonJ.M. DevitoJ.A. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization J. Antimicrob. Chemother. 67 2814 2820 2012 10.1093/jac/dks30722875850 Search in Google Scholar

93 Sader H.S., Biedenbach D.J., Paukner S., Ivezic-Schoenfeld Z., Jones R.N.: Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56, 1619–1623 (2012) SaderH.S. BiedenbachD.J. PauknerS. Ivezic-SchoenfeldZ. JonesR.N. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections Antimicrob. Agents Chemother. 56 1619 1623 2012 10.1128/AAC.05789-11329490722232289 Search in Google Scholar

94 Sader H.S., Paukner S., Ivezic-Schoenfeld Z., Biedenbach D.J., Schmitz F.J., Jones R.N.: Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J. Antimicrob. Chemother. 67, 1170–1175 (2012) SaderH.S. PauknerS. Ivezic-SchoenfeldZ. BiedenbachD.J. SchmitzF.J. JonesR.N. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs) J. Antimicrob. Chemother. 67 1170 1175 2012 10.1093/jac/dks00122287234 Search in Google Scholar

95 Sadowy E.: Mobile genetic elements beyond the VanB-resistance dissemination among hospital-associated enterococci and other Gram-positive bacteria. Plasmid, 114, DOI:10.1016/j.plasmid.2021.102558 (2021) SadowyE. Mobile genetic elements beyond the VanB-resistance dissemination among hospital-associated enterococci and other Gram-positive bacteria Plasmid 114 10.1016/j.plasmid.2021.102558 2021 33472048 Open DOISearch in Google Scholar

96 Sato T., Yamawaki K.: Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin. Clin. Infect. Dis. 69, 538–543 (2019) SatoT. YamawakiK. Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin Clin. Infect. Dis. 69 538 543 2019 10.1093/cid/ciz826685375931724047 Search in Google Scholar

97 Savov E., Trifonova A., Kovachka K., Kjosseva E., Strateva T.: Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa – a pilot Bulgarian study. Infect. Dis. 51, 870–873 (2019) SavovE. TrifonovaA. KovachkaK. KjossevaE. StratevaT. Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa – a pilot Bulgarian study Infect. Dis. 51 870 873 2019 10.1080/23744235.2019.165349131433679 Search in Google Scholar

98 Shi Y., Hua X., Xu Q., Yang Y., Zhang L., He J., Mu X., Hu L., Leptihn S., Yu Y.: Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC. Infect. Genet. Evol. 80, DOI:10.1016/j.meegid.2020.104185 (2020) ShiY. HuaX. XuQ. YangY. ZhangL. HeJ. MuX. HuL. LeptihnS. YuY. Mechanism of eravacycline resistance in Acinetobacter baumannii mediated by a deletion mutation in the sensor kinase adeS, leading to elevated expression of the efflux pump AdeABC Infect. Genet. Evol. 80 10.1016/j.meegid.2020.104185 2020 31923725 Open DOISearch in Google Scholar

99 Shortridge D., Pfaller M.A., Streit J.M., Flamm R.K.: Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014–2019). J. Glob. Antimicrob. Resist. 23, 278–283 (2020) ShortridgeD. PfallerM.A. StreitJ.M. FlammR.K. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014–2019) J. Glob. Antimicrob. Resist. 23 278 283 2020 10.1016/j.jgar.2020.09.02733068780 Search in Google Scholar

100 Siala W., Mingeot-Leclercq M.P., Tulkens P.M., Hallin M., Denis O., Van Bambeke F.: Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 58, 6385–6397 (2014) SialaW. Mingeot-LeclercqM.P. TulkensP.M. HallinM. DenisO. Van BambekeF. Comparison of the antibiotic activities of daptomycin, vancomycin, and the investigational fluoroquinolone delafloxacin against biofilms from Staphylococcus aureus clinical isolates Antimicrob. Agents Chemother. 58 6385 6397 2014 10.1128/AAC.03482-14424940025114142 Search in Google Scholar

101 Sims M., Mariyanovski V., McLeroth P., Akers W., Lee Y.C., Brown M.L., Du J., Pedley A., Kartsonis N.A., Paschke A.: Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J. Antimicrob. Chemother. 72, 2616–2626 (2017) SimsM. MariyanovskiV. McLerothP. AkersW. LeeY.C. BrownM.L. DuJ. PedleyA. KartsonisN.A. PaschkeA. Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections J. Antimicrob. Chemother. 72 2616 2626 2017 10.1093/jac/dkx13928575389 Search in Google Scholar

102 Słoczyńska A., Wand M.E., Tyski S., Laudy A.E.: Analysis of bla_CHDL genes and insertion sequences related to carbapenem resistance in Acinetobacter baumannii clinical strains isolated in Warsaw, Poland. Int. J. Mol. Sci. 22, DOI:10.3390/ijms22052486 (2021) SłoczyńskaA. WandM.E. TyskiS. LaudyA.E. Analysis of bla_CHDL genes and insertion sequences related to carbapenem resistance in Acinetobacter baumannii clinical strains isolated in Warsaw, Poland Int. J. Mol. Sci. 22 10.3390/ijms22052486 2021 795789333801221 Open DOISearch in Google Scholar

103 Snydman D.R., McDermott L.A., Jacobus N.V., Kerstein K., Grossman T.H., Sutcliffe J.A.: Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates. Antimicrob. Agents Chemother. 62, DOI: 10.1128/aac.02206-17 (2018) SnydmanD.R. McDermottL.A. JacobusN.V. KersteinK. GrossmanT.H. SutcliffeJ.A. Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates Antimicrob. Agents Chemother. 62 10.1128/aac.02206-17 2018 Open DOISearch in Google Scholar

104 Solomkin J.S., Gardovskis J., Lawrence K., Montravers P., Sway A., Evans D., Tsai L.: IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin. Infect. Dis. 69, 921–929 (2019) SolomkinJ.S. GardovskisJ. LawrenceK. MontraversP. SwayA. EvansD. TsaiL. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections Clin. Infect. Dis. 69 921 929 2019 10.1093/cid/ciy1029673568730561562 Search in Google Scholar

105 Solomkin J.S., Ramesh M.K., Cesnauskas G., Novikovs N., Stefanova P., Sutcliffe J.A., Walpole S.M., Horn P.T.: Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob. Agents Chemother. 58, 1847–1854 (2014) SolomkinJ.S. RameshM.K. CesnauskasG. NovikovsN. StefanovaP. SutcliffeJ.A. WalpoleS.M. HornP.T. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections Antimicrob. Agents Chemother. 58 1847 1854 2014 10.1128/AAC.01614-13402372024342651 Search in Google Scholar

106 Stracquadanio S., Torti E., Longshaw C., Henriksen A.S., Stefani S.: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy. J. Glob. Antimicrob. Resist. 25, 390–398 (2021) StracquadanioS. TortiE. LongshawC. HenriksenA.S. StefaniS. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in Italy J. Glob. Antimicrob. Resist. 25 390 398 2021 10.1016/j.jgar.2021.04.01934020073 Search in Google Scholar

107 Sun C., Wang Q., Brubaker J.D., Wright P.M., Lerner C.D., Noson K., Charest M., Siegel D.R., Wang Y.M., Myers A.G.: A robust platform for the synthesis of new tetracycline antibiotics. J. Am. Chem. Soc. 130, 17913–17927 (2008) SunC. WangQ. BrubakerJ.D. WrightP.M. LernerC.D. NosonK. CharestM. SiegelD.R. WangY.M. MyersA.G. A robust platform for the synthesis of new tetracycline antibiotics J. Am. Chem. Soc. 130 17913 17927 2008 10.1021/ja806629e268126719053822 Search in Google Scholar

108 Sun D., Rubio-Aparicio D., Nelson K., Dudley M.N., Lomovskaya O.: Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.01694-17 (2017) SunD. Rubio-AparicioD. NelsonK. DudleyM.N. LomovskayaO. Meropenem-vaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae Antimicrob. Agents Chemother. 61 10.1128/aac.01694-17 2017 570031029038260 Open DOISearch in Google Scholar

109 Sun J., Liu Y.H., et al.: Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli. Nat. Microbiol. 4, 1457–1464 (2019) SunJ. LiuY.H. Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli Nat. Microbiol. 4 1457 1464 2019 10.1038/s41564-019-0496-4670786431235960 Search in Google Scholar

110 Sutcliffe J.A., O’Brien W., Fyfe C., Grossman T.H.: Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 57, 5548–5558 (2013) SutcliffeJ.A. O’BrienW. FyfeC. GrossmanT.H. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens Antimicrob. Agents Chemother. 57 5548 5558 2013 10.1128/AAC.01288-13381127723979750 Search in Google Scholar

111 Tsivkovski R., Lomovskaya O.: Biochemical activity of vaborbactam. Antimicrob. Agents Chemother. 64, DOI: 10.1128/aac.01935-19 (2020) TsivkovskiR. LomovskayaO. Biochemical activity of vaborbactam Antimicrob. Agents Chemother. 64 10.1128/aac.01935-19 2020 Open DOISearch in Google Scholar

112 Tulkens P.M., Van Bambeke F., Zinner S.H.: Profile of a novel anionic fluoroquinolone-delafloxacin. Clin. Infect. Dis. 68, 213–222 (2019) TulkensP.M. Van BambekeF. ZinnerS.H. Profile of a novel anionic fluoroquinolone-delafloxacin Clin. Infect. Dis. 68 213 222 2019 10.1093/cid/ciy1079645200130957164 Search in Google Scholar

113 Waites K.B., Crabb D.M., Duffy L.B.: Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob. Agents Chemother. 47, 3973–3975 (2003) WaitesK.B. CrabbD.M. DuffyL.B. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas Antimicrob. Agents Chemother. 47 3973 3975 2003 10.1128/AAC.47.12.3973-3975.200329622114638513 Search in Google Scholar

114 Waites K.B., Crabb D.M., Duffy L.B., Jensen J.S., Liu Y., Paukner S.: In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob. Agents Chemother. 61, DOI: 10.1128/aac.02008-16 (2017) WaitesK.B. CrabbD.M. DuffyL.B. JensenJ.S. LiuY. PauknerS. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China Antimicrob. Agents Chemother. 61 10.1128/aac.02008-16 2017 Open DOISearch in Google Scholar

115 Walkty A., Karlowsky J.A., Baxter M.R., Adam H.J., Golden A., Lagace-Wiens P., Zhanel G.G.: In vitro activity of imipenemrelebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016–2019. Diag. Microbiol. Infect. Dis. 101, DOI:10.1016/j.diagmicrobio.2021.115418 (2021) WalktyA. KarlowskyJ.A. BaxterM.R. AdamH.J. GoldenA. Lagace-WiensP. ZhanelG.G. In vitro activity of imipenemrelebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016–2019 Diag. Microbiol. Infect. Dis. 101 10.1016/j.diagmicrobio.2021.115418 2021 34102373 Open DOISearch in Google Scholar

116 Wang L., Walsh T.R., et al.: Novel plasmid-mediated tet(X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii isolate. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.01326-19 (2019) WangL. WalshT.R. Novel plasmid-mediated tet(X5) gene conferring resistance to tigecycline, eravacycline, and omadacycline in a clinical Acinetobacter baumannii isolate Antimicrob. Agents Chemother. 64 10.1128/aac.01326-19 2019 718758831611352 Open DOISearch in Google Scholar

117 Wang Z., Lin Z., Bai B., Xu G., Li P., Yu Z., Deng Q., Shang Y., Zheng J.: Eravacycline susceptibility was impacted by genetic mutation of 30S ribosome subunits, and branched-chain amino acid transport system II carrier protein, Na/Pi cotransporter family protein in Staphylococcus aureus. BMC Microbiol. 20, DOI:10.1186/s12866-020-01869-6 (2020) WangZ. LinZ. BaiB. XuG. LiP. YuZ. DengQ. ShangY. ZhengJ. Eravacycline susceptibility was impacted by genetic mutation of 30S ribosome subunits, and branched-chain amino acid transport system II carrier protein, Na/Pi cotransporter family protein in Staphylococcus aureus BMC Microbiol. 20 10.1186/s12866-020-01869-6 2020 732944132611319 Open DOISearch in Google Scholar

118 Wen Z., Shang Y., Xu G., Pu Z., Lin Z., Bai B., Chen Z., Zheng J., Deng Q., Yu Z.: Mechanism of eravacycline resistance in clinical Enterococcus faecalis isolates from China. Front. Microbiol. 11, DOI:10.3389/fmicb.2020.00916 (2020) WenZ. ShangY. XuG. PuZ. LinZ. BaiB. ChenZ. ZhengJ. DengQ. YuZ. Mechanism of eravacycline resistance in clinical Enterococcus faecalis isolates from China Front. Microbiol. 11 10.3389/fmicb.2020.00916 2020 726185432523563 Open DOISearch in Google Scholar

119 Wilson B.R., Bogdan A.R., Miyazawa M., Hashimoto K., Tsuji Y.: Siderophores in iron metabolism: from mechanism to therapy potential. Trends Mol. Med. 22, 1077–1090 (2016) WilsonB.R. BogdanA.R. MiyazawaM. HashimotoK. TsujiY. Siderophores in iron metabolism: from mechanism to therapy potential Trends Mol. Med. 22 1077 1090 2016 10.1016/j.molmed.2016.10.005513558727825668 Search in Google Scholar

120 World Health Organization: 2020 antibacterial agents in clinical and preclinical development: an overview and analysis. http://apps.who.int/iris/handle/10665/340694 (16.07.2021) World Health Organization 2020 antibacterial agents in clinical and preclinical development: an overview and analysis http://apps.who.int/iris/handle/10665/340694 (16.07.2021) Search in Google Scholar

121 World Health Organization: Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. https://apps.who.int/iris/handle/10665/311820 (16.07.2021) World Health Organization Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis https://apps.who.int/iris/handle/10665/311820 (16.07.2021) Search in Google Scholar

122 Wunderink R.G., Nagata T.D., et al.: Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 21, 213–225 (2021) WunderinkR.G. NagataT.D. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial Lancet Infect. Dis. 21 213 225 2021 10.1016/S1473-3099(20)30731-333058798 Search in Google Scholar

123 Xiao X.Y., Sutcliffe J.A., et al.: Fluorocyclines. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. J. Med. Chem. 55, 597–605 (2012) XiaoX.Y. SutcliffeJ.A. Fluorocyclines. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent J. Med. Chem. 55 597 605 2012 10.1021/jm201465w22148514 Search in Google Scholar

124 Young K., Motyl M.R., et al.: In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol. 19, DOI:10.1186/s12866-019-1522-7 (2019) YoungK. MotylM.R. In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa BMC Microbiol. 19 10.1186/s12866-019-1522-7 2019 661093831272373 Open DOISearch in Google Scholar

125 Zhanel G.G., Baxter M.R., Adam H.J., Sutcliffe J., Karlowsky J.A.: In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diag. Microbiol. Infect. Dis. 91, 55–62 (2018) ZhanelG.G. BaxterM.R. AdamH.J. SutcliffeJ. KarlowskyJ.A. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015 Diag. Microbiol. Infect. Dis. 91 55 62 2018 10.1016/j.diagmicrobio.2017.12.01329338931 Search in Google Scholar

126 Zhanel G.G., Karlowsky J.A., et al.: Lefamulin: a novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia. Drugs, 81, 233–256 (2021) ZhanelG.G. KarlowskyJ.A. Lefamulin: a novel oral and intravenous pleuromutilin for the treatment of community-acquired bacterial pneumonia Drugs 81 233 256 2021 10.1007/s40265-020-01443-433247830 Search in Google Scholar

127 Zhang F., Yu Z.J., et al.: Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance. BMC Microbiol. 18, DOI:10.1186/s12866-018-1349-7 (2018) ZhangF. YuZ.J. Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance BMC Microbiol. 18 10.1186/s12866-018-1349-7 2018 629359030545293 Open DOISearch in Google Scholar

128 Zheng J.X., Lin Z.W., Sun X., Lin W.H., Chen Z., Wu Y., Qi G.B., Deng Q.W., Qu D., Yu Z.J.: Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae. Emerg. Microbes Infect. 7, DOI:10.1038/s41426-018-0141-y (2018) ZhengJ.X. LinZ.W. SunX. LinW.H. ChenZ. WuY. QiG.B. DengQ.W. QuD. YuZ.J. Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae Emerg. Microbes Infect. 7 10.1038/s41426-018-0141-y 2018 607057230068997 Open DOISearch in Google Scholar

129 Zhou M., Yang Q., Lomovskaya O., Sun D., Kudinha T., Xu Z., Zhang G., Chen X., Xu Y.: In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China. Antimicrob. Chemother. 73, 2789–2796 (2018) ZhouM. YangQ. LomovskayaO. SunD. KudinhaT. XuZ. ZhangG. ChenX. XuY. In vitro activity of meropenem combined with vaborbactam against KPC-producing Enterobacteriaceae in China Antimicrob. Chemother. 73 2789 2796 2018 10.1093/jac/dky25129982437 Search in Google Scholar

130 Zhuchenko G., Schmidt-Malan S., Patel R.: Planktonic and biofilm activity of eravacycline against Staphylococci isolated from periprosthetic joint infections. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.01304-20 (2020) ZhuchenkoG. Schmidt-MalanS. PatelR. Planktonic and biofilm activity of eravacycline against Staphylococci isolated from periprosthetic joint infections Antimicrob. Agents Chemother. 64 10.1128/aac.01304-20 2020 Open DOISearch in Google Scholar

1 Abdallah M., Olafisoye O., Cortes C., Urban C., Landman D., Quale J.: Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother. 59, 1802–1805 (2015) AbdallahM. OlafisoyeO. CortesC. UrbanC. LandmanD. QualeJ. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City Antimicrob. Agents Chemother. 59 1802 1805 2015 10.1128/AAC.04809-14432580925534744 Search in Google Scholar

2 Alexander E., Schranz J. i wsp.: Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. Jama, 322, 1661–1671 (2019) AlexanderE. SchranzJ. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial Jama 322 1661 1671 2019 10.1001/jama.2019.15468686522431560372 Search in Google Scholar

3 Almer L.S., Hoffrage J.B., Keller E.L., Flamm R.K., Shortridge V.D.: In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 48, 2771–2777 (2004) AlmerL.S. HoffrageJ.B. KellerE.L. FlammR.K. ShortridgeV.D. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms Antimicrob. Agents Chemother. 48 2771 2777 2004 10.1128/AAC.48.7.2771-2777.200443420115215148 Search in Google Scholar

4 Ambler R.P.: The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289, 321–331 (1980) AmblerR.P. The structure of β-lactamases Philos. Trans. R. Soc. Lond. B Biol. Sci. 289 321 331 1980 10.1098/rstb.1980.00496109327 Search in Google Scholar

5 Aoki T., Yamano Y. i wsp.: Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship. Eur. J. Med. Chem. 155, 847–868 (2018) AokiT. YamanoY. Cefiderocol (S-649266), a new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens including multi-drug resistant bacteria: structure activity relationship Eur. J. Med. Chem. 155 847 868 2018 10.1016/j.ejmech.2018.06.01429960205 Search in Google Scholar

6 Asempa T.E., Nicolau D.P., Kuti J.L.: In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 63, DOI: 10.1128/aac.00997-19 (2019) AsempaT.E. NicolauD.P. KutiJ.L. In vitro activity of imipenem-relebactam alone or in combination with amikacin or colistin against Pseudomonas aeruginosa Antimicrob. Agents Chemother. 63 10.1128/aac.00997-19 2019 Open DOISearch in Google Scholar

7 Barnes M.D., Bethel C.R., Alsop J., Becka S.A., Rutter J.D., Papp-Wallace K.M., Bonomo R.A.: Inactivation of the Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam. Antimicrob. Agents Chemother. 62, DOI: 10.1128/aac.02406-17 (2018) BarnesM.D. BethelC.R. AlsopJ. BeckaS.A. RutterJ.D. Papp-WallaceK.M. BonomoR.A. Inactivation of the Pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam Antimicrob. Agents Chemother. 62 10.1128/aac.02406-17 2018 Open DOISearch in Google Scholar

8 Bassetti M., Nagata T.D. i wsp.: Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect. Dis. 21, 226–240 (2021) BassettiM. NagataT.D. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial Lancet Infect. Dis. 21 226 240 2021 10.1016/S1473-3099(20)30796-933058795 Search in Google Scholar

9 Bassetti M., Giacobbe D.R., Patel N., Tillotson G., Massey J.: Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis. Adv. Ther. 36, 1771–1777 (2019) BassettiM. GiacobbeD.R. PatelN. TillotsonG. MasseyJ. Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: a post hoc analysis Adv. Ther. 36 1771 1777 2019 10.1007/s12325-019-00981-y682445931098989 Search in Google Scholar

10 Bhowmick T.: Clinical outcomes of patient subgroups in the TANGO II study. Infect. Dis. Ther. 10, 35–46 (2021) BhowmickT. Clinical outcomes of patient subgroups in the TANGO II study Infect. Dis. Ther. 10 35 46 2021 10.1007/s40121-021-00405-x787211333565042 Search in Google Scholar

11 Biagi M., Wu T., Lee M., Patel S., Butler D., Wenzler E.: Searching for the optimal treatment for metallo- and serine-β-Lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob. Agents Chemother. 63, DOI: 10.1128/aac.01426-19 (2019) BiagiM. WuT. LeeM. PatelS. ButlerD. WenzlerE. Searching for the optimal treatment for metallo- and serine-β-Lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam Antimicrob. Agents Chemother. 63 10.1128/aac.01426-19 2019 Open DOISearch in Google Scholar

12 Blizzard T.A., Hammond M.L. i wsp.: Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin^®. Bioorg. Med. Chem. Lett. 24, 780–785 (2014) BlizzardT.A. HammondM.L. Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin^® Bioorg. Med. Chem. Lett. 24 780 785 2014 10.1016/j.bmcl.2013.12.10124433862 Search in Google Scholar

13 Brodersen D.E., Clemons W.M., Jr., Carter A.P., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V.: The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell, 103, 1143–1154 (2000) BrodersenD.E. ClemonsW.M.Jr. CarterA.P. Morgan-WarrenR.J. WimberlyB.T. RamakrishnanV. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit Cell 103 1143 1154 2000 10.1016/S0092-8674(00)00216-611163189 Search in Google Scholar

14 Castanheira M., Huband M.D., Mendes R.E., Flamm R.K.: Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 61, e00567–17 (2017) CastanheiraM. HubandM.D. MendesR.E. FlammR.K. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae Antimicrob. Agents Chemother. 61 e00567 17 2017 10.1128/AAC.00567-17557130428652234 Search in Google Scholar

15 Castanheira M., Rhomberg P.R., Flamm R.K., Jones R.N.: Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 60, 5454–5458 (2016) CastanheiraM. RhombergP.R. FlammR.K. JonesR.N. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae Antimicrob. Agents Chemother. 60 5454 5458 2016 10.1128/AAC.00711-16499782227381386 Search in Google Scholar

16 Chen C., Liu Y.H. i wsp.: Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species. Genome Med. 12, DOI:10.1186/s13073-020-00807-5 (2020) ChenC. LiuY.H. Genetic diversity and characteristics of high-level tigecycline resistance Tet(X) in Acinetobacter species Genome Med. 12 10.1186/s13073-020-00807-5 2020 772244933287863 Open DOISearch in Google Scholar

17 Chen C., Sun J. i wsp.: Emergence of mobile tigecycline resistance mechanism in Escherichia coli strains from migratory birds in China. Emerg. Microbes Infect. 8, 1219–1222 (2019) ChenC. SunJ. Emergence of mobile tigecycline resistance mechanism in Escherichia coli strains from migratory birds in China Emerg. Microbes Infect. 8 1219 1222 2019 10.1080/22221751.2019.1653795671315531429665 Search in Google Scholar

18 Ding Y., Saw W.Y., Tan L.W.L., Moong D.K.N., Nagarajan N., Teo Y.Y., Seedorf H.: Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans. J. Antimicrob. Chemother. 75, 3480–3484 (2020) DingY. SawW.Y. TanL.W.L. MoongD.K.N. NagarajanN. TeoY.Y. SeedorfH. Emergence of tigecycline- and eravacycline-resistant Tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans J. Antimicrob. Chemother. 75 3480 3484 2020 10.1093/jac/dkaa37232853333 Search in Google Scholar

19 Durka K., Laudy A.E., Charzewski Ł., Urban M., Stępień K., Tyski S., Krzyśko K.A., Luliński S.: Antimicrobial and KPC/AmpC inhibitory activity of functionalized benzosiloxaboroles. Eur. J. Med. Chem. 171, 11–24 (2019) DurkaK. LaudyA.E. CharzewskiŁ. UrbanM. StępieńK. TyskiS. KrzyśkoK.A. LulińskiS. Antimicrobial and KPC/AmpC inhibitory activity of functionalized benzosiloxaboroles Eur. J. Med. Chem. 171 11 24 2019 10.1016/j.ejmech.2019.03.02830904754 Search in Google Scholar

20 European Medicines Agency: Medicines. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human (16.07.2021) European Medicines Agency Medicines https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human (16.07.2021) Search in Google Scholar

21 Eyal Z., Matzov D., Krupkin M., Paukner S., Riedl R., Rozenberg H., Zimmerman E., Bashan A., Yonath A.: A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci. Rep. 6, DOI:10.1038/srep39004 (2016) EyalZ. MatzovD. KrupkinM. PauknerS. RiedlR. RozenbergH. ZimmermanE. BashanA. YonathA. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism Sci. Rep. 6 10.1038/srep39004 2016 515418827958389 Open DOISearch in Google Scholar

22 File T.M., Gasink L.B. i wsp.: Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin. Infect. Dis. 69, 1856–1867 (2019) FileT.M. GasinkL.B. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial Clin. Infect. Dis. 69 1856 1867 2019 10.1093/cid/ciz090685369430722059 Search in Google Scholar

23 Fyfe C., LeBlanc G., Close B., Nordmann P., Dumas J., Grossman T.H.: Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1. Antimicrob. Agents Chemother. 60, 6989–6990 (2016) FyfeC. LeBlancG. CloseB. NordmannP. DumasJ. GrossmanT.H. Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1 Antimicrob. Agents Chemother. 60 6989 6990 2016 10.1128/AAC.01646-16507512627550359 Search in Google Scholar

24 Gaibani P., Lombardo D., Bussini L., Bovo F., Munari B., Giannella M., Bartoletti M., Viale P., Lazzarotto T., Ambretti S.: Epidemiology of meropenem/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018. Antibiotics, 10, DOI:10.3390/antibiotics10050536 (2021) GaibaniP. LombardoD. BussiniL. BovoF. MunariB. GiannellaM. BartolettiM. VialeP. LazzarottoT. AmbrettiS. Epidemiology of meropenem/vaborbactam resistance in KPC-producing Klebsiella pneumoniae causing bloodstream infections in northern Italy, 2018 Antibiotics 10 10.3390/antibiotics10050536 2021 814811934066420 Open DOISearch in Google Scholar

25 Gainey A.B., Burch A.K., Brownstein M.J., Brown D.E., Fackler J., Horne B., Biswas B., Bivens B.N., Malagon F., Daniels R.: Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr. Pulmonol. 55, 2990–2994 (2020) GaineyA.B. BurchA.K. BrownsteinM.J. BrownD.E. FacklerJ. HorneB. BiswasB. BivensB.N. MalagonF. DanielsR. Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient Pediatr. Pulmonol. 55 2990 2994 2020 10.1002/ppul.2494532662948 Search in Google Scholar

26 Ghai I., Ghai S.: Exploring bacterial outer membrane barrier to combat bad bugs. Infect. Drug Resist. 10, 261–273 (2017) GhaiI. GhaiS. Exploring bacterial outer membrane barrier to combat bad bugs Infect. Drug Resist. 10 261 273 2017 10.2147/IDR.S144299558713128919790 Search in Google Scholar

27 Giacobbe D.R., Ciacco E., Girmenia C., Pea F., Rossolini G.M., Sotgiu G., Tascini C., Tumbarello M., Viale P., Bassetti M.: Evaluating cefiderocol in the treatment of multidrug-resistant Gram-negative bacilli: a review of the emerging data. Infect. Drug Resist. 13, 4697–4711 (2020) GiacobbeD.R. CiaccoE. GirmeniaC. PeaF. RossoliniG.M. SotgiuG. TasciniC. TumbarelloM. VialeP. BassettiM. Evaluating cefiderocol in the treatment of multidrug-resistant Gram-negative bacilli: a review of the emerging data Infect. Drug Resist. 13 4697 4711 2020 10.2147/IDR.S205309777837833402840 Search in Google Scholar

28 Giulieri S.G., Tong S.Y.C., Williamson D.A.: Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections. Microb. Genom. 6, DOI: 10.1099/mgen.0.000324 (2020) GiulieriS.G. TongS.Y.C. WilliamsonD.A. Using genomics to understand meticillin- and vancomycin-resistant Staphylococcus aureus infections Microb. Genom. 6 10.1099/mgen.0.000324 2020 706703331913111 Open DOISearch in Google Scholar

29 Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., Fernandez H.T.: In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob. Agents Chemother. 47, 3008–3011 (2003) GoldsteinE.J. CitronD.M. MerriamC.V. WarrenY.A. TyrrellK.L. FernandezH.T. In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis Antimicrob. Agents Chemother. 47 3008 3011 2003 10.1128/AAC.47.9.3008-3011.200318260212937015 Search in Google Scholar

30 Gomez-Simmonds A., Stump S., Giddins M.J., Annavajhala M.K., Uhlemann A.C.: Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae Antimicrob. Agents Chemother. 62, DOI:10.1128/aac.00573-18 (2018) Gomez-SimmondsA. StumpS. GiddinsM.J. AnnavajhalaM.K. UhlemannA.C. Clonal background, resistance gene profile, and porin gene mutations modulate in vitro susceptibility to imipenem-relebactam in diverse Enterobacteriaceae Antimicrob Agents Chemother. 62 10.1128/aac.00573-18 2018 Open DOISearch in Google Scholar

31 Grossman T.H.: Tetracycline antibiotics and resistance. Cold Spring Harb. Perspect. Med. 6, DOI:10.1101/cshperspect.a025387 (2016) GrossmanT.H. Tetracycline antibiotics and resistance Cold Spring Harb. Perspect. Med. 6 10.1101/cshperspect.a025387 2016 481774026989065 Open DOISearch in Google Scholar

32 Grossman T.H., O’Brien W., Kerstein K.O., Sutcliffe J.A.: Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob. Agents Chemother. 59, 2446–2449 (2015) GrossmanT.H. O’BrienW. KersteinK.O. SutcliffeJ.A. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli Antimicrob. Agents Chemother. 59 2446 2449 2015 10.1128/AAC.04967-14435679225624334 Search in Google Scholar

33 Grossman T.H., Starosta A.L., Fyfe C., O’Brien W., Rothstein D.M., Mikolajka A., Wilson D.N., Sutcliffe J.A.: Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob. Agents Chemother. 56, 2559–2564 (2012) GrossmanT.H. StarostaA.L. FyfeC. O’BrienW. RothsteinD.M. MikolajkaA. WilsonD.N. SutcliffeJ.A. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic Antimicrob. Agents Chemother. 56 2559 2564 2012 10.1128/AAC.06187-11334660522354310 Search in Google Scholar

34 Gunderson S.M., Hayes R.A., Quinn J.P., Danziger L.H.: In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 48, 203–208 (2004) GundersonS.M. HayesR.A. QuinnJ.P. DanzigerL.H. In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Antimicrob. Agents Chemother. 48 203 208 2004 10.1128/AAC.48.1.203-208.200431016614693540 Search in Google Scholar

35 Hackel M.A., Tsuji M., Yamano Y., Echols R., Karlowsky J.A., Sahm D.F.: In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob. Agents Chemother. 62, DOI:10.1128/aac.01968-17 (2018) HackelM.A. TsujiM. YamanoY. EcholsR. KarlowskyJ.A. SahmD.F. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016 Antimicrob. Agents Chemother. 62 10.1128/aac.01968-17 2018 578675529158270 Open DOISearch in Google Scholar

36 Haidar G., Clancy C.J., Chen L., Samanta P., Shields R.K., Kreiswirth B.N., Nguyen M.H.: Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.00642-17 (2017) HaidarG. ClancyC.J. ChenL. SamantaP. ShieldsR.K. KreiswirthB.N. NguyenM.H. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae Antimicrob. Agents Chemother. 61 10.1128/aac.00642-17 2017 557134328630202 Open DOISearch in Google Scholar

37 Hammoudi Halat D., Ayoub Moubareck C.: The current burden of carbapenemases: review of significant properties and dissemination among Gram-negative bacteria. Antibiotics, 9, DOI:10.3390/antibiotics9040186 (2020) Hammoudi HalatD. Ayoub MoubareckC. The current burden of carbapenemases: review of significant properties and dissemination among Gram-negative bacteria Antibiotics 9 10.3390/antibiotics9040186 2020 723576932316342 Open DOISearch in Google Scholar

38 He D., Wang L., Zhao S., Liu L., Liu J., Hu G., Pan Y.: A novel tigecycline resistance gene, tet(X6), on an SXT/R391 integrative and conjugative element in a Proteus genomospecies 6 isolate of retail meat origin. J. Antimicrob. Chemother. 75, 1159–1164 (2020) HeD. WangL. ZhaoS. LiuL. LiuJ. HuG. PanY. A novel tigecycline resistance gene, tet(X6), on an SXT/R391 integrative and conjugative element in a Proteus genomospecies 6 isolate of retail meat origin J. Antimicrob. Chemother. 75 1159 1164 2020 10.1093/jac/dkaa01232016288 Search in Google Scholar

39 Hecker S.J., Dudley M.N. i wsp.: Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J. Med. Chem. 58, 3682–3692 (2015) HeckerS.J. DudleyM.N. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases J. Med. Chem. 58 3682 3692 2015 10.1021/acs.jmedchem.5b0012725782055 Search in Google Scholar

40 Hirsch E.B., Ledesma K.R., Chang K.T., Schwartz M.S., Motyl M.R., Tam V.H.: In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 56, 3753–3757 (2012) HirschE.B. LedesmaK.R. ChangK.T. SchwartzM.S. MotylM.R. TamV.H. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria Antimicrob. Agents Chemother. 56 3753 3757 2012 10.1128/AAC.05927-11339346022526311 Search in Google Scholar

41 Hook E.W., 3rd, Golden M.R., Taylor S.N., Henry E., Tseng C., Workowski K.A., Swerdlow J., Nenninger A., Cammarata S.: Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study. Sex. Transm. Dis. 46, 279–286 (2019) HookE.W.3rd GoldenM.R. TaylorS.N. HenryE. TsengC. WorkowskiK.A. SwerdlowJ. NenningerA. CammarataS. Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study Sex. Transm. Dis. 46 279 286 2019 10.1097/OLQ.000000000000097130985632 Search in Google Scholar

42 Hooper D.C., Jacoby G.A.: Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 6, DOI:10.1101/cshperspect.a025320 (2016) HooperD.C. JacobyG.A. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance Cold Spring Harb. Perspect. Med. 6 10.1101/cshperspect.a025320 2016 500806027449972 Open DOISearch in Google Scholar

43 Hoover R., Hunt T., Benedict M., Paulson S.K., Lawrence L., Cammarata S., Sun E.: Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin. Ther. 38, 53–65 (2016) HooverR. HuntT. BenedictM. PaulsonS.K. LawrenceL. CammarataS. SunE. Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers Clin. Ther. 38 53 65 2016 10.1016/j.clinthera.2015.11.01926718605 Search in Google Scholar

44 Hoover R., Hunt T., Benedict M., Paulson S.K., Lawrence L., Cammarata S., Sun E.: Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin. Ther. 38, 39–52 (2016) HooverR. HuntT. BenedictM. PaulsonS.K. LawrenceL. CammarataS. SunE. Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age Clin. Ther. 38 39 52 2016 10.1016/j.clinthera.2015.10.01626581327 Search in Google Scholar

45 Horcajada J.P., Salata R.A., Álvarez-Sala R., Nitu F.M., Lawrence L., Quintas M., Cheng C.Y., Cammarata S.: A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect. Dis. 7, DOI:10.1093/ofid/ofz514 (2020) HorcajadaJ.P. SalataR.A. Álvarez-SalaR. NituF.M. LawrenceL. QuintasM. ChengC.Y. CammarataS. A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP) Open Forum Infect. Dis. 7 10.1093/ofid/ofz514 2020 697525131988972 Open DOISearch in Google Scholar

46 Ito-Horiyama T., Ishii Y., Ito A., Sato T., Nakamura R., Fukuhara N., Tsuji M., Yamano Y., Yamaguchi K., Tateda K.: Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob. Agents Chemother. 60, 4384–4386 (2016) Ito-HoriyamaT. IshiiY. ItoA. SatoT. NakamuraR. FukuharaN. TsujiM. YamanoY. YamaguchiK. TatedaK. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases Antimicrob. Agents Chemother. 60 4384 4386 2016 10.1128/AAC.03098-15491468827139465 Search in Google Scholar

47 Ito A., Nishikawa T., Ota M., Ito-Horiyama T., Ishibashi N., Sato T., Tsuji M., Yamano Y.: Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J. Antimicrob. Chemother. 73, 3049–3052 (2018) ItoA. NishikawaT. OtaM. Ito-HoriyamaT. IshibashiN. SatoT. TsujiM. YamanoY. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae J. Antimicrob. Chemother. 73 3049 3052 2018 10.1093/jac/dky317619874330188999 Search in Google Scholar

48 Ito A., Yamano Y. i wsp.: In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob. Agents Chemother. 62, DOI:10.1128/aac.01454-17 (2018) ItoA. YamanoY. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria Antimicrob. Agents Chemother. 62 10.1128/aac.01454-17 2018 Open DOISearch in Google Scholar

49 Jacobsson S., Paukner S., Golparian D., Jensen J.S., Unemo M.: In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.01497-17 (2017) JacobssonS. PauknerS. GolparianD. JensenJ.S. UnemoM. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively drug-resistant Neisseria gonorrhoeae Antimicrob. Agents Chemother. 61 10.1128/aac.01497-17 2017 Open DOISearch in Google Scholar

50 Johnson J.R., Porter S.B., Johnston B.D., Thuras P.: Activity of eravacycline against Escherichia coli clinical isolates collected from U.S. veterans in 2011 in relation to coresistance phenotype and sequence Type 131 genotype. Antimicrob. Agents Chemother. 60, 1888–1891 (2015) JohnsonJ.R. PorterS.B. JohnstonB.D. ThurasP. Activity of eravacycline against Escherichia coli clinical isolates collected from U.S. veterans in 2011 in relation to coresistance phenotype and sequence Type 131 genotype Antimicrob. Agents Chemother. 60 1888 1891 2015 10.1128/AAC.02403-15477594126666925 Search in Google Scholar

51 Johnston B.D., Thuras P., Porter S.B., Anacker M., VonBank B., Vagnone P.S., Witwer M., Castanheira M., Johnson J.R.: Activity of imipenem-relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.02408-19 (2020) JohnstonB.D. ThurasP. PorterS.B. AnackerM. VonBankB. VagnoneP.S. WitwerM. CastanheiraM. JohnsonJ.R. Activity of imipenem-relebactam against carbapenem-resistant Escherichia coli isolates from the United States in relation to clonal background, resistance genes, coresistance, and region Antimicrob. Agents Chemother. 64 10.1128/aac.02408-19 2020 Open DOISearch in Google Scholar

52 Johnston B.D., Thuras P., Porter S.B., Castanheira M., Johnson J.R.: Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region. J. Glob. Antimicrob. Resist. 24, 190–197 (2021) JohnstonB.D. ThurasP. PorterS.B. CastanheiraM. JohnsonJ.R. Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region J. Glob. Antimicrob. Resist. 24 190 197 2021 10.1016/j.jgar.2020.12.01733460842 Search in Google Scholar

53 Karlowsky J.A., Lob S.H., Kazmierczak K.M., Hawser S.P., Magnet S., Young K., Motyl M.R., Sahm D.F.: In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J. Antimicrob. Chemother. 73, 1872–1879 (2018) KarlowskyJ.A. LobS.H. KazmierczakK.M. HawserS.P. MagnetS. YoungK. MotylM.R. SahmD.F. In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme J. Antimicrob. Chemother. 73 1872 1879 2018 10.1093/jac/dky10729659861 Search in Google Scholar

54 Karlowsky J.A., Lob S.H., Kazmierczak K.M., Young K., Motyl M.R., Sahm D.F.: In vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017. Int. J. Antimicrob. Agents, 55, DOI:10.1016/j.ijantimicag.2019.10.022 (2020) KarlowskyJ.A. LobS.H. KazmierczakK.M. YoungK. MotylM.R. SahmD.F. In vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients – SMART Surveillance United States 2015–2017 Int. J. Antimicrob. Agents 55 10.1016/j.ijantimicag.2019.10.022 2020 31704217 Open DOISearch in Google Scholar

55 Kaye K.S., Giamarellos-Bourboulis E.J. i wsp.: Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. Jama, 319, 788–799 (2018) KayeK.S. Giamarellos-BourboulisE.J. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial Jama 319 788 799 2018 10.1001/jama.2018.0438583865629486041 Search in Google Scholar

56 Kingsley J., Mehra P., Lawrence L.E., Henry E., Duffy E., Cammarata S.K., Pullman J.: A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J. Antimicrob. Chemother. 71, 821–829 (2016) KingsleyJ. MehraP. LawrenceL.E. HenryE. DuffyE. CammarataS.K. PullmanJ. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin J. Antimicrob. Chemother. 71 821 829 2016 10.1093/jac/dkv411474370326679243 Search in Google Scholar

57 Kocsis B., Domokos J., Szabo D.: Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann. Clin. Microbiol. Antimicrob. 15, DOI:10.1186/s12941-016-0150-4 (2016) KocsisB. DomokosJ. SzaboD. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin Ann. Clin. Microbiol. Antimicrob. 15 10.1186/s12941-016-0150-4 2016 487806727215369 Open DOISearch in Google Scholar

58 Kohira N., Hackel M.A., Ishioka Y., Kuroiwa M., Sahm D.F., Sato T., Maki H., Yamano Y.: Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J. Glob. Antimicrob. Resist. 22, 738–741 (2020) KohiraN. HackelM.A. IshiokaY. KuroiwaM. SahmD.F. SatoT. MakiH. YamanoY. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014) J. Glob. Antimicrob. Resist. 22 738 741 2020 10.1016/j.jgar.2020.07.00932702396 Search in Google Scholar

59 Lapuebla A., Abdallah M., Olafisoye O., Cortes C., Urban C., Quale J., Landman D.: Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob. Agents Chemother. 59, 4856–4860 (2015) LapueblaA. AbdallahM. OlafisoyeO. CortesC. UrbanC. QualeJ. LandmanD. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City Antimicrob. Agents Chemother. 59 4856 4860 2015 10.1128/AAC.00843-15450529326033723 Search in Google Scholar

60 Laudy A.E.: Systemy MDR – istotny mechanizm oporności pałeczek Gram-ujemnych na antybiotyki i chemioterapeutyki. Post. Mikrobiol. 47, 415–422 (2008) LaudyA.E. Systemy MDR – istotny mechanizm oporności pałeczek Gram-ujemnych na antybiotyki i chemioterapeutyki Post. Mikrobiol. 47 415 422 2008 Search in Google Scholar

61 Li P., Wei Y., Li G., Cheng H., Xu Z., Yu Z., Deng Q., Shi Y.: Comparison of antimicrobial efficacy of eravacycline and tigecycline against clinical isolates of Streptococcus agalactiae in China: In vitro activity, heteroresistance, and cross-resistance. Microb. Pathog. 149, DOI:10.1016/j.micpath.2020.104502 (2020) LiP. WeiY. LiG. ChengH. XuZ. YuZ. DengQ. ShiY. Comparison of antimicrobial efficacy of eravacycline and tigecycline against clinical isolates of Streptococcus agalactiae in China: In vitro activity, heteroresistance, and cross-resistance Microb. Pathog. 149 10.1016/j.micpath.2020.104502 2020 32947016 Open DOISearch in Google Scholar

62 Livermore D.M., Mushtaq S., Warner M., Woodford N.: In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob. Agents Chemother. 60, 3840–3844 (2016) LivermoreD.M. MushtaqS. WarnerM. WoodfordN. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii Antimicrob. Agents Chemother. 60 3840 3844 2016 10.1128/AAC.00436-16487938227044556 Search in Google Scholar

63 Livermore D.M., Warner M., Mushtaq S.: Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 68, 2286–2290 (2013) LivermoreD.M. WarnerM. MushtaqS. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa J. Antimicrob. Chemother. 68 2286 2290 2013 10.1093/jac/dkt17823696619 Search in Google Scholar

64 Lob S.H., Hackel M.A., Kazmierczak K.M., Young K., Motyl M.R., Karlowsky J.A., Sahm D.F.: In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.02209-16 (2017) LobS.H. HackelM.A. KazmierczakK.M. YoungK. MotylM.R. KarlowskyJ.A. SahmD.F. In vitro activity of imipenem-relebactam against Gram-negative ESKAPE pathogens isolated by clinical laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program) Antimicrob. Agents Chemother. 61 10.1128/aac.02209-16 2017 544418428320716 Open DOISearch in Google Scholar

65 Lob S.H., Karlowsky J.A., Young K., Motyl M.R., Hawser S., Kothari N.D., Sahm D.F.: In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017. J. Med. Microbiol. 69, 207–217 (2020) LobS.H. KarlowskyJ.A. YoungK. MotylM.R. HawserS. KothariN.D. SahmD.F. In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017 J. Med. Microbiol. 69 207 217 2020 10.1099/jmm.0.00114231976856 Search in Google Scholar

66 Lomovskaya O., Sun D., Rubio-Aparicio D., Nelson K., Tsivkovski R., Griffith D.C., Dudley M.N.: Vaborbactam: spectrum of β-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.01443-17 (2017) LomovskayaO. SunD. Rubio-AparicioD. NelsonK. TsivkovskiR. GriffithD.C. DudleyM.N. Vaborbactam: spectrum of β-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae Antimicrob. Agents Chemother. 61 10.1128/aac.01443-17 2017 Open DOISearch in Google Scholar

67 Lucasti C., Paschke A. i wsp.: Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob. Agents Chemother. 60, 6234–6243 (2016) LucastiC. PaschkeA. Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection Antimicrob. Agents Chemother. 60 6234 6243 2016 10.1128/AAC.00633-16503831327503659 Search in Google Scholar

68 Lv L., Liu J.H. i wsp.: Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae. mBio, 11, DOI:10.1128/mBio.02930-19 (2020) LvL. LiuJ.H. Emergence of a plasmid-encoded resistance-nodulation-division efflux pump conferring resistance to multiple drugs, including tigecycline, in Klebsiella pneumoniae mBio 11 10.1128/mBio.02930-19 2020 706476932127452 Open DOISearch in Google Scholar

69 Malik S., Kaminski M., Landman D., Quale J.: Cefiderocol resistance in Acinetobacter baumannii: roles of β-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.01221-20 (2020) MalikS. KaminskiM. LandmanD. QualeJ. Cefiderocol resistance in Acinetobacter baumannii: roles of β-lactamases, siderophore receptors, and penicillin binding protein 3 Antimicrob. Agents Chemother. 64 10.1128/aac.01221-20 2020 Open DOISearch in Google Scholar

70 Maraki S., Mavromanolaki V.E., Moraitis P., Stafylaki D., Kasimati A., Magkafouraki E., Scoulica E.: Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. DOI:10.1007/s10096-021-04197-3 (2021) MarakiS. MavromanolakiV.E. MoraitisP. StafylakiD. KasimatiA. MagkafourakiE. ScoulicaE. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae Eur. J. Clin. Microbiol. Infect. Dis. 10.1007/s10096-021-04197-3 2021 33595756 Open DOISearch in Google Scholar

71 McCurdy S., Keedy K., Lawrence L., Nenninger A., Sheets A., Quintas M., Cammarata S.: Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial. Antimicrob. Agents Chemother. 64, DOI:10.1128/aac.01949-19 (2020) McCurdyS. KeedyK. LawrenceL. NenningerA. SheetsA. QuintasM. CammarataS. Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial Antimicrob. Agents Chemother. 64 10.1128/aac.01949-19 2020 703830731844013 Open DOISearch in Google Scholar

72 McCurdy S., Lawrence L., Quintas M., Woosley L., Flamm R., Tseng C., Cammarata S.: In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 61, DOI:10.1128/aac.00772-17 (2017) McCurdyS. LawrenceL. QuintasM. WoosleyL. FlammR. TsengC. CammarataS. In vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections Antimicrob. Agents Chemother. 61 10.1128/aac.00772-17 2017 Open DOISearch in Google Scholar

73 McCurdy S., Nenninger A., Sheets A., Keedy K., Lawrence L., Quintas M., Cammarata S.: Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial. Int. J. Infect. Dis. 97, 374–379 (2020) McCurdyS. NenningerA. SheetsA. KeedyK. LawrenceL. QuintasM. CammarataS. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial Int. J. Infect. Dis. 97 374 379 2020 10.1016/j.ijid.2020.06.01832534142 Search in Google Scholar

74 Mendes R.E., Farrell D.J., Flamm R.K., Talbot G.H., Ivezic-Schoenfeld Z., Paukner S., Sader H.S.: In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob. Agents Chemother. 60, 4407–4411 (2016) MendesR.E. FarrellD.J. FlammR.K. TalbotG.H. Ivezic-SchoenfeldZ. PauknerS. SaderH.S. In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States Antimicrob. Agents Chemother. 60 4407 4411 2016 10.1128/AAC.00627-16491467527161634 Search in Google Scholar

75 Mendes R.E., Paukner S., Doyle T.B., Gelone S.P., Flamm R.K., Sader H.S.: Low prevalence of Gram-positive isolates showing elevated lefamulin MIC. Results during the SENTRY Surveillance Program for 2015–2016 and characterization of resistance mechanisms. Antimicrob. Agents Chemother. 63, DOI:10.1128/aac.02158-18 (2019) MendesR.E. PauknerS. DoyleT.B. GeloneS.P. FlammR.K. SaderH.S. Low prevalence of Gram-positive isolates showing elevated lefamulin MIC. Results during the SENTRY Surveillance Program for 2015–2016 and characterization of resistance mechanisms Antimicrob. Agents Chemother. 63 10.1128/aac.02158-18 2019 Open DOISearch in Google Scholar

76 Morrissey I., Hawser S., Lob S.H., Karlowsky J.A., Bassetti M., Corey G.R., Olesky M., Newman J., Fyfe C.: In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI: 10.1128/aac.01715-19 (2020) MorrisseyI. HawserS. LobS.H. KarlowskyJ.A. BassettiM. CoreyG.R. OleskyM. NewmanJ. FyfeC. In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013 to 2017 Antimicrob. Agents Chemother. 64 10.1128/aac.01715-19 2020 Open DOISearch in Google Scholar

77 Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C.: In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI: 10.1128/aac.01699-19 (2020) MorrisseyI. OleskyM. HawserS. LobS.H. KarlowskyJ.A. CoreyG.R. BassettiM. FyfeC. In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017 Antimicrob. Agents Chemother. 64 10.1128/aac.01699-19 2020 703830331843999 Open DOISearch in Google Scholar

78 Motsch J., Paschke A. i wsp.: RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin. Infect. Dis. 70, 1799–1808 (2020) MotschJ. PaschkeA. RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections Clin. Infect. Dis. 70 1799 1808 2020 10.1093/cid/ciz530715677431400759 Search in Google Scholar

79 Namysłowska A., Laudy A.E., Tyski S.: Mechanizmy oporności Acinetobacter baumannii na związki przeciwbakteryjne. Post. Mikrobiol. 54, 392–406 (2015) NamysłowskaA. LaudyA.E. TyskiS. Mechanizmy oporności Acinetobacter baumannii na związki przeciwbakteryjne Post. Mikrobiol. 54 392 406 2015 Search in Google Scholar

80 Negash K.H., Norris J.K.S., Hodgkinson J.T.: Siderophore-antibiotic conjugate design: new drugs for bad bugs? Molecules, 24, DOI:10.3390/molecules24183314 (2019) NegashK.H. NorrisJ.K.S. HodgkinsonJ.T. Siderophore-antibiotic conjugate design: new drugs for bad bugs? Molecules 24 10.3390/molecules24183314 2019 676707831514464 Open DOISearch in Google Scholar

81 Nilius A.M., Shen L.L., Hensey-Rudloff D., Almer L.S., Beyer J.M., Balli D.J., Cai Y., Flamm R.K.: In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. 47, 3260–3269 (2003) NiliusA.M. ShenL.L. Hensey-RudloffD. AlmerL.S. BeyerJ.M. BalliD.J. CaiY. FlammR.K. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone Antimicrob. Agents Chemother. 47 3260 3269 2003 10.1128/AAC.47.10.3260-3269.200320115314506039 Search in Google Scholar

82 O’Riordan W., McManus A., Teras J., Poromanski I., Cruz-Saldariagga M., Quintas M., Lawrence L., Liang S., Cammarata S.: A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure snfections: a phase 3, multinational, souble-blind, randomized study. Clin. Infect. Dis. 67, 657–666 (2018) O’RiordanW. McManusA. TerasJ. PoromanskiI. Cruz-SaldariaggaM. QuintasM. LawrenceL. LiangS. CammarataS. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure snfections: a phase 3, multinational, souble-blind, randomized study Clin. Infect. Dis. 67 657 666 2018 10.1093/cid/ciy165609399529518178 Search in Google Scholar

83 O’Riordan W., Mehra P., Manos P., Kingsley J., Lawrence L., Cammarata S.: A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int. J. Infect. Dis. 30, 67–73 (2015) O’RiordanW. MehraP. ManosP. KingsleyJ. LawrenceL. CammarataS. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections Int. J. Infect. Dis. 30 67 73 2015 10.1016/j.ijid.2014.10.00925448332 Search in Google Scholar

84 Ozger H.S., Cuhadar T., Yildiz S.S., Demirbas Gulmez Z., Dizbay M., Guzel Tunccan O., Kalkanci A., Simsek H., Unaldi O.: In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates. J. Antibiot. 72, 600–604 (2019) OzgerH.S. CuhadarT. YildizS.S. Demirbas GulmezZ. DizbayM. Guzel TunccanO. KalkanciA. SimsekH. UnaldiO. In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates J. Antibiot. 72 600 604 2019 10.1038/s41429-019-0188-631028352 Search in Google Scholar

85 Paukner S., Gelone S.P., Arends S.J.R., Flamm R.K., Sader H.S.: Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016). Antimicrob. Agents Chemother. 63, DOI:10.1128/aac.02161-18 (2019) PauknerS. GeloneS.P. ArendsS.J.R. FlammR.K. SaderH.S. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015–2016) Antimicrob. Agents Chemother. 63 10.1128/aac.02161-18 2019 Open DOISearch in Google Scholar

86 Paukner S., Riedl R.: Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb. Perspect. Med. 7, DOI:10.1101/cshperspect.a027110 (2017) PauknerS. RiedlR. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance Cold Spring Harb. Perspect. Med. 7 10.1101/cshperspect.a027110 2017 520432727742734 Open DOISearch in Google Scholar

87 Paukner S., Sader H.S., Ivezic-Schoenfeld Z., Jones R.N.: Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob. Agents Chemother. 57, 4489–4495 (2013) PauknerS. SaderH.S. Ivezic-SchoenfeldZ. JonesR.N. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010 Antimicrob. Agents Chemother. 57 4489 4495 2013 10.1128/AAC.00358-13375434023836172 Search in Google Scholar

88 Pfaller M.A., Huband M.D., Mendes R.E., Flamm R.K., Castanheira M.: In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Int. J. Antimicrob. Agents, 52, 144–150 (2018) PfallerM.A. HubandM.D. MendesR.E. FlammR.K. CastanheiraM. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme Int. J. Antimicrob. Agents 52 144 150 2018 10.1016/j.ijantimicag.2018.02.02129510189 Search in Google Scholar

89 Portsmouth S., van Veenhuyzen D., Echols R., Machida M., Ferreira J.C.A., Ariyasu M., Tenke P., Nagata T.D.: Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 18, 1319–1328 (2018) PortsmouthS. van VeenhuyzenD. EcholsR. MachidaM. FerreiraJ.C.A. AriyasuM. TenkeP. NagataT.D. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial Lancet Infect. Dis. 18 1319 1328 2018 10.1016/S1473-3099(18)30554-130509675 Search in Google Scholar

90 Prince W.T., Ivezic-Schoenfeld Z., Lell C., Tack K.J., Novak R., Obermayr F., Talbot G.H.: Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 57, 2087–2094 (2013) PrinceW.T. Ivezic-SchoenfeldZ. LellC. TackK.J. NovakR. ObermayrF. TalbotG.H. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections Antimicrob. Agents Chemother. 57 2087 2094 2013 10.1128/AAC.02106-12363289223422913 Search in Google Scholar

91 Pullman J., Gardovskis J., Farley B., Sun E., Quintas M., Lawrence L., Ling R., Cammarata S.: Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J. Antimicrob. Chemother. 72, 3471–3480 (2017) PullmanJ. GardovskisJ. FarleyB. SunE. QuintasM. LawrenceL. LingR. CammarataS. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study J. Antimicrob. Chemother. 72 3471 3480 2017 10.1093/jac/dkx329589068629029278 Search in Google Scholar